Latest Breaking News On - New anticancer drugs - Page 1 : comparemela.com

AstraZeneca, Daiichi Sankyo gets Chinese nod for Enhertu as first HER2-directed therapy for patients with HER2-low metastatic breast cancer

Enhertu is a HER2-directed ADC.

United statesKiminori nagaoBinghe xuDaiichi sankyoDave fredricksonDepartment of medical oncologyCancer hospital chinese academy of medical sciencesChina national medical products administrationNational clinical research centerAmerican society of clinical oncologyUnion medical collegeNational medical products administrationAmerican societyClinical oncologyNew england journalNew anticancer drugs

China Approves Enhertu as First HER2-Directed Therapy for HER2-Low Metastatic Breast Cancer

China Approves Enhertu as First HER2-Directed Therapy for HER2-Low Metastatic Breast Cancer
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United statesBinghe xuDave fredricksonKiminori nagaoDaiichi sankyoDaiichi sankyo enhertuDepartment of medical oncologyUnion medical collegeCancer hospital chinese academy of medical sciencesChina national medical products administrationNational clinical research centerAmerican society of clinical oncologyNational medical products administrationAmerican societyClinical oncologyNew england journal

AstraZeneca (AZN) reports Enhertu approved in China as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer

AstraZeneca (AZN) reports Enhertu approved in China as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesDaiichi sankyoKiminori nagaoDaiichi sankyo enhertuBinghe xuDave fredricksonCancer hospital chinese academy of medical sciencesUnion medical collegeNational clinical research centerChina national medical products administrationAmerican society of clinical oncologyDepartment of medical oncologyNational medical products administrationAmerican societyClinical oncologyNew england journal

Trastuzumab Deruxtecan Approved in China for HER2-Low Metastatic Breast Cancer

China’s National Medical Products Administration has approved trastuzumab deruxtecan monotherapy in adult patients with unresectable or metastatic HER2-low breast cancer who have previously received a systemic therapy in the metastatic setting or whose disease recurred during or within 6 months of adjuvant chemotherapy.

Binghe xuDaiichi sankyoChina national medical products administrationUnion medical collegeNational clinical research centerNational medical products administrationNew anticancer drugsMedical oncologyCancer hospital chinese academyMedical sciencesPeking union medical collegeNational medical products administration of chinaTrastuzumab deruxtecanUnresectable or metastatic her2 low breast cancer